Suppr超能文献

先天免疫炎症细胞死亡:宿主防御和疾病中的 PANoptosis 和 PANoptosomes。

Innate immune inflammatory cell death: PANoptosis and PANoptosomes in host defense and disease.

机构信息

Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.

出版信息

Eur J Immunol. 2023 Nov;53(11):e2250235. doi: 10.1002/eji.202250235. Epub 2023 Mar 3.

Abstract

Regulated cell death (RCD) triggered by innate immune activation is an important strategy for host survival during pathogen invasion and perturbations of cellular homeostasis. There are two main categories of RCD, including nonlytic and lytic pathways. Apoptosis is the most well-characterized nonlytic RCD, and the inflammatory pyroptosis and necroptosis pathways are among the best known lytic forms. While these were historically viewed as independent RCD pathways, extensive evidence of cross-talk among their molecular components created a knowledge gap in our mechanistic understanding of RCD and innate immune pathway components, which led to the identification of PANoptosis. PANoptosis is a unique innate immune inflammatory RCD pathway that is regulated by PANoptosome complexes upon sensing pathogens, pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs) or the cytokines produced downstream. Cytosolic innate immune sensors and regulators, such as ZBP1, AIM2 and RIPK1, promote the assembly of PANoptosomes to drive PANoptosis. In this review, we discuss the molecular components of the known PANoptosomes and highlight the mechanisms of PANoptosome assembly, activation and regulation identified to date. We also discuss how PANoptosomes and mutations in PANoptosome components are linked to diseases. Given the impact of RCD, and PANoptosis specifically, across the disease spectrum, improved understanding of PANoptosomes and their regulation will be critical for identifying new therapeutic targets and strategies.

摘要

受固有免疫激活触发的调控细胞死亡 (RCD) 是宿主在病原体入侵和细胞稳态失调时存活的重要策略。RCD 有两种主要类型,包括非溶细胞性和溶细胞性途径。细胞凋亡是最典型的非溶细胞性 RCD,而炎症性细胞焦亡和坏死性细胞凋亡途径是最著名的溶细胞形式。虽然这些途径在历史上被视为独立的 RCD 途径,但它们的分子成分之间广泛的相互作用证据在我们对 RCD 和固有免疫途径成分的机制理解方面造成了知识空白,从而导致了 PANoptosis 的发现。PANoptosis 是一种独特的固有免疫炎症性 RCD 途径,当感知病原体、病原体相关分子模式 (PAMPs)、损伤相关分子模式 (DAMPs) 或下游产生的细胞因子时,由 PANoptosome 复合物调节。细胞质固有免疫传感器和调节剂,如 ZBP1、AIM2 和 RIPK1,促进 PANoptosome 的组装以驱动 PANoptosis。在这篇综述中,我们讨论了已知的 PANoptosome 的分子成分,并强调了迄今为止确定的 PANoptosome 组装、激活和调节的机制。我们还讨论了 PANoptosome 和 PANoptosome 成分中的突变如何与疾病相关。鉴于 RCD,特别是 PANoptosis,在疾病谱中的广泛影响,对 PANoptosome 及其调节的深入了解对于确定新的治疗靶点和策略至关重要。

相似文献

1
Innate immune inflammatory cell death: PANoptosis and PANoptosomes in host defense and disease.
Eur J Immunol. 2023 Nov;53(11):e2250235. doi: 10.1002/eji.202250235. Epub 2023 Mar 3.
2
Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes.
Trends Mol Med. 2024 Jan;30(1):74-88. doi: 10.1016/j.molmed.2023.10.001. Epub 2023 Nov 15.
4
PANoptosis: Emerging mechanisms and disease implications.
Life Sci. 2023 Nov 15;333:122158. doi: 10.1016/j.lfs.2023.122158. Epub 2023 Oct 6.
7
Single cell analysis of PANoptosome cell death complexes through an expansion microscopy method.
Cell Mol Life Sci. 2022 Sep 28;79(10):531. doi: 10.1007/s00018-022-04564-z.
8
PANoptosome signaling and therapeutic implications in infection: central role for ZBP1 to activate the inflammasome and PANoptosis.
Curr Opin Immunol. 2023 Aug;83:102348. doi: 10.1016/j.coi.2023.102348. Epub 2023 May 31.
10
PANoptosis: A Unique Innate Immune Inflammatory Cell Death Modality.
J Immunol. 2022 Nov 1;209(9):1625-1633. doi: 10.4049/jimmunol.2200508.

引用本文的文献

1
PANoptosis in cancer: molecular mechanisms and therapeutic potential.
Cancer Gene Ther. 2025 Aug 21. doi: 10.1038/s41417-025-00940-6.
2
Diverse functions of NLRP3 inflammasome in PANoptosis and diseases.
Cell Death Discov. 2025 Aug 19;11(1):389. doi: 10.1038/s41420-025-02689-1.
3
Three decades of caspases and RIPKs in life and death.
Hum Mol Genet. 2025 Jul 25. doi: 10.1093/hmg/ddaf106.
4
PANoptosis in neurological disorders: mechanisms, implications, and therapeutic potential.
Front Immunol. 2025 Jun 11;16:1579360. doi: 10.3389/fimmu.2025.1579360. eCollection 2025.
5
HCK regulates NLRP12-mediated PANoptosis.
Proc Natl Acad Sci U S A. 2025 May 27;122(21):e2422079122. doi: 10.1073/pnas.2422079122. Epub 2025 May 23.
7
Modeling Necroptotic and Pyroptotic Signaling in .
Biomolecules. 2025 Apr 4;15(4):530. doi: 10.3390/biom15040530.
10
Innate immune sensor NLRP3 drives PANoptosome formation and PANoptosis.
J Immunol. 2025 Apr 18. doi: 10.1093/jimmun/vkaf042.

本文引用的文献

1
ADAR1 and ZBP1 in innate immunity, cell death, and disease.
Trends Immunol. 2023 Mar;44(3):201-216. doi: 10.1016/j.it.2023.01.001. Epub 2023 Jan 27.
2
Pancancer transcriptomic profiling identifies key PANoptosis markers as therapeutic targets for oncology.
NAR Cancer. 2022 Nov 1;4(4):zcac033. doi: 10.1093/narcan/zcac033. eCollection 2022 Dec.
3
Single cell analysis of PANoptosome cell death complexes through an expansion microscopy method.
Cell Mol Life Sci. 2022 Sep 28;79(10):531. doi: 10.1007/s00018-022-04564-z.
4
ADAR1 mutation causes ZBP1-dependent immunopathology.
Nature. 2022 Jul;607(7920):769-775. doi: 10.1038/s41586-022-04896-7. Epub 2022 Jul 20.
5
ADAR1 averts fatal type I interferon induction by ZBP1.
Nature. 2022 Jul;607(7920):776-783. doi: 10.1038/s41586-022-04878-9. Epub 2022 Jul 20.
6
ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation.
Nature. 2022 Jul;607(7920):784-789. doi: 10.1038/s41586-022-04974-w. Epub 2022 Jul 20.
7
ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis.
Nature. 2022 Jun;606(7914):594-602. doi: 10.1038/s41586-022-04753-7. Epub 2022 May 25.
10
STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS).
Cell Death Dis. 2022 Mar 25;13(3):269. doi: 10.1038/s41419-022-04664-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验